Abstract: Olaparib (AZD2281) is a pioneering, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that has significantly transformed the therapeutic landscape for breast cancer, particularly in patients harboring germline BRCA1 and BRCA2 mutations. By exploiting the molecular concept of synthetic lethality, olaparib induces targeted cancer cell death in tumors deficient in homologous recombination repair. Extensive clinical evaluation, highlighted by the pivotal OlympiAD and OlympiA trials, has demonstrated substantial improvements in progression-free survival and invasive disease-free survival in both metastatic and early-stage breast cancer settings. Despite its remarkable clinical efficacy, the use of olaparib is associated with challenges, including hematological toxicities and the emergence of acquired drug resistance. Current research is heavily focused on overcoming these limitations through novel combination therapies—such as pairing olaparib with PI3K/AKT inhibitors or immunotherapies—and expanding its clinical utility to broader patient populations with homologous recombination deficiencies beyond germline BRCA mutations.
1. Introduction
Breast cancer remains one of the most frequently diagnosed malignancies globally and presents significant therapeutic challenges, particularly in its triple-negative (TNBC) and HER2-negative subtypes. Approximately 5% to 10% of all breast tumors are associated with inherited mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 [12]. Olaparib (AZD2281) is a first-in-class, orally administered inhibitor of the poly(ADP-ribose) polymerase (PARP) enzyme family, specifically targeting PARP1, PARP2, and PARP3 [1]. It was the first PARP inhibitor to demonstrate superior efficacy and tolerability compared to standard chemotherapy in patients with germline BRCA-mutated (gBRCAm) advanced breast cancer [65]. Based on robust clinical data, the US Food and Drug Administration (FDA) granted approval for olaparib in January 2018 for the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer [1][13]. Its introduction into clinical practice represents a major milestone in precision oncology, offering a targeted approach that capitalizes on the specific genetic vulnerabilities of BRCA-mutated tumors.
2. Pharmacological Activity
The pharmacological efficacy of olaparib in breast cancer has been rigorously established across multiple pivotal clinical trials, demonstrating significant benefits in both metastatic and adjuvant settings. In the metastatic setting, the Phase III OlympiAD trial evaluated olaparib monotherapy against the physician's choice of standard chemotherapy (capecitabine, eribulin, or vinorelbine) in patients with gBRCAm, HER2-negative metastatic breast cancer [7][13]. Olaparib significantly prolonged median progression-free survival (PFS) to 7.0 months compared to 4.2 months in the standard therapy group (Hazard Ratio [HR] 0.58; p < 0.001) [7][16]. Furthermore, the objective response rate (ORR) was approximately doubled in the olaparib arm (59.9% vs. 28.8%) [7][37]. Patients receiving olaparib also experienced a significant delay in the deterioration of global health-related quality of life [7].
In the early-stage (adjuvant) setting, the Phase III OlympiA trial investigated the use of olaparib in patients with high-risk, HER2-negative early breast cancer harboring gBRCA1/2 mutations who had completed local treatment and neoadjuvant or adjuvant chemotherapy [12][14]. Olaparib demonstrated a statistically significant improvement in 3-year invasive disease-free survival (IDFS) (85.9% vs. 77.1%) and distant disease-free survival (DDFS) (87.5% vs. 80.4%) compared to placebo [14][35]. Extended follow-up of the OlympiA trial revealed a sustained overall survival (OS) benefit, showing a 32% reduction in mortality risk at four years (HR 0.68; p = 0.009) [14].
3. Molecular Mechanism of Action
Olaparib exerts its potent anti-tumor effects primarily through the molecular mechanism of "synthetic lethality," a phenomenon where the simultaneous loss of two specific genes or pathways results in cell death, whereas the loss of either alone is viable [3][13]. In normal cellular homeostasis, PARP1 and PARP2 enzymes are essential for detecting and repairing single-strand DNA breaks (SSBs) via the base excision repair (BER) pathway [52][74]. Olaparib functions by inhibiting the catalytic activity of PARP and, crucially, by trapping the PARP-DNA complex at replication forks [13][74]. This trapping prevents the repair of SSBs, which subsequently collapse during DNA replication and are converted into highly toxic double-strand breaks (DSBs) [40][74].
In healthy cells, these DSBs are accurately repaired by the homologous recombination repair (HRR) pathway, heavily reliant on functional BRCA1 and BRCA2 proteins. However, in cancer cells harboring deleterious BRCA1 or BRCA2 mutations, the HRR pathway is fundamentally defective [40][52]. Consequently, these BRCA-deficient cells are forced to rely on error-prone DNA repair mechanisms, such as non-homologous end joining (NHEJ). The reliance on NHEJ in the presence of olaparib-induced DSBs leads to severe genomic instability, chromosomal aberrations, disruption of cellular homeostasis, and ultimately, apoptotic cell death [1][40][100].
4. Structure-Activity Relationship (SAR)
Olaparib (AZD2281, KU-0059436) was developed through the optimization of a series of substituted 4-benzyl-2H-phthalazin-1-ones. Chemically, it is identified as 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one [100]. This specific structural configuration allows olaparib to act as a highly potent, nanomolar inhibitor of PARP1 and PARP2 [100]. The phthalazinone core mimics the nicotinamide moiety of NAD+, binding competitively to the catalytic domain of PARP enzymes. Beyond simple catalytic inhibition, olaparib's structure enables it to effectively trap PARP1 and PARP2 enzymes onto damaged DNA [18][52]. While olaparib exhibits significant PARP trapping activity, comparative preclinical studies indicate that other PARP inhibitors, such as talazoparib, possess up to 100 times greater PARP-trapping potential [67]. Nevertheless, olaparib's specific binding profile and trapping efficiency provide an optimal therapeutic window, inducing robust synthetic lethality in BRCA-deficient cells without causing insurmountable toxicity in normal tissues [18][100].
5. Current Limitations
Despite its clinical success, the use of olaparib is constrained by adverse events (AEs) and the development of acquired drug resistance. The most frequently reported AEs include nausea, fatigue, vomiting, and hematological toxicities [12][13]. Grade 3/4 AEs are predominantly hematological; early trials reported neutropenia in approximately 40% of patients, anemia in 15–22%, and thrombocytopenia in 20% [1][19]. These toxicities can necessitate dose interruptions, reductions, or discontinuation of therapy, potentially compromising treatment efficacy [37].
Furthermore, resistance to PARP inhibitors inevitably develops in a subset of patients. Known mechanisms of resistance include secondary restoring mutations in BRCA1/2 that re-establish the open reading frame and restore homologous recombination proficiency [25]. Additionally, the upregulation and induction of ABCB1 (MDR1) efflux pumps have been identified as a common mechanism driving resistance to olaparib [31]. Clinical observations also indicate that patients previously treated with platinum-based chemotherapy often derive less benefit from olaparib, suggesting overlapping resistance mechanisms between platinum agents and PARP inhibitors [33].
6. Future Perspectives
To overcome resistance mechanisms and enhance clinical efficacy, future research is heavily focused on combination therapies and expanding patient eligibility criteria. Olaparib is currently being investigated in combination with immune checkpoint inhibitors, such as durvalumab (e.g., in the MEDIOLA trial), to leverage potential synergies between DNA damage and immune activation [27][60]. Additionally, combining olaparib with PI3K/AKT pathway inhibitors—such as capivasertib (ComPAKT trial) or the pan-PI3K inhibitor buparlisib (BKM120)—has shown promise in preclinical and early clinical settings by inducing a state of "BRCAness" in HR-proficient tumors [8][53].
Clinical trials are also exploring the utility of olaparib beyond germline BRCA mutations. Emerging data suggest efficacy in patients with somatic BRCA mutations or mutations in other HRR-related genes (e.g., PALB2, ATM, CHEK2) [40][46]. Finally, expanding the use of olaparib into earlier stages of breast cancer, including neoadjuvant settings and high-risk adjuvant populations (such as in the ongoing SUBITO trial), continues to be a promising avenue to maximize long-term survival and potentially cure BRCA-associated breast cancers [17][57].
